Literature DB >> 8225873

Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone.

J R Samples1, J P Alexander, T S Acott.   

Abstract

PURPOSE: The regulation of the trabecular meshwork's extracellular matrix is poorly understood and may involve a family of secreted proteinases, the matrix metalloproteinases. Because the trabecular extracellular matrix has been hypothesized to affect intraocular pressure, an evaluation was made of the ability of two cellular modulators to change the levels of matrix metalloproteinases in the medium of human trabecular meshwork organ explant cultures.
METHODS: Trabecular explant cultures were exposed to recombinant human interleukin-1 alpha, dexamethasone, or combinations thereof for 72 hours and the culture medium was collected for analysis. Levels of stromelysin, the 72 kD gelatinase A and the 92 kD gelatinase B enzyme activity in this culture medium were assayed by substrate gel electrophoresis (zymography). Stromelysin and the tissue inhibitor of metalloproteinases (TIMP1) media protein levels were analyzed using immunoblots of Western transfers.
RESULTS: Culture medium of unstimulated explants contains significant levels of the 72 kD gelatinase A and only low levels of the 92 kD gelatinase B, stromelysin, and TIMP1. Interleukin-1 alpha produces a dose-dependent several-fold elevation of gelatinase B, stromelysin, and TIMP1 without changing gelatinase A levels. Dexamethasone produces no significant change in gelatinase A and only small increases in stromelysin, gelatinase B, and TIMP1. When added together, dexamethasone antagonizes the interleukin-1 alpha-induced increase of stromelysin, gelatinase B, and TIMP1 in a dose-dependent manner.
CONCLUSION: These modulators may be useful in analyzing the roles of this enzyme family in normal trabecular homeostasis and perhaps in the etiology of glaucoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8225873

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  34 in total

1.  Interactions between endothelia of the trabecular meshwork and of Schlemm's canal: a new insight into the regulation of aqueous outflow in the eye.

Authors:  Jorge A Alvarado; Ru-Fang Yeh; Linda Franse-Carman; George Marcellino; Michael J Brownstein
Journal:  Trans Am Ophthalmol Soc       Date:  2005

Review 2.  Extracellular matrix in the trabecular meshwork.

Authors:  Ted S Acott; Mary J Kelley
Journal:  Exp Eye Res       Date:  2008-01-25       Impact factor: 3.467

3.  Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice.

Authors:  Darryl R Overby; Jacques Bertrand; Ozan-Yüksel Tektas; Alexandra Boussommier-Calleja; Martin Schicht; C Ross Ethier; David F Woodward; W Daniel Stamer; Elke Lütjen-Drecoll
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-07-15       Impact factor: 4.799

Review 4.  Corticosteroids and glaucoma risk.

Authors:  R C Tripathi; S K Parapuram; B J Tripathi; Y Zhong; K V Chalam
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

Review 5.  Role of the alternatively spliced glucocorticoid receptor isoform GRβ in steroid responsiveness and glaucoma.

Authors:  Ankur Jain; Robert J Wordinger; Thomas Yorio; Abbot F Clark
Journal:  J Ocul Pharmacol Ther       Date:  2014-02-07       Impact factor: 2.671

Review 6.  Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.

Authors:  M Elizabeth Fini; Stephen G Schwartz; Xiaoyi Gao; Shinwu Jeong; Nitin Patel; Tatsuo Itakura; Marianne O Price; Francis W Price; Rohit Varma; W Daniel Stamer
Journal:  Prog Retin Eye Res       Date:  2016-09-22       Impact factor: 21.198

7.  Latanoprost-induced changes in rat intraocular pressure: direct or indirect?

Authors:  Shahid Husain; Phillip W Yates; Craig E Crosson
Journal:  J Ocul Pharmacol Ther       Date:  2008-08       Impact factor: 2.671

8.  Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma.

Authors:  Maria-Grazia Spiga; Teresa Borrás
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

9.  Immunohistochemical evaluation of the extracellular matrix in trabecular meshwork in steroid-induced glaucoma.

Authors:  Akihiko Tawara; Norihiko Tou; Toshiaki Kubota; Yukinori Harada; Kiyomi Yokota
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-02       Impact factor: 3.117

10.  Bioengineered glaucomatous 3D human trabecular meshwork as an in vitro disease model.

Authors:  Karen Y Torrejon; Ellen L Papke; Justin R Halman; Judith Stolwijk; Cula N Dautriche; Magnus Bergkvist; John Danias; Susan T Sharfstein; Yubing Xie
Journal:  Biotechnol Bioeng       Date:  2015-12-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.